These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28752982)

  • 41. Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials.
    Kim J; Schell MJ
    Oncotarget; 2019 Jul; 10(42):4255-4261. PubMed ID: 31303960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 43. How large should a phase II trial of a new drug be?
    Simon R
    Cancer Treat Rep; 1987 Nov; 71(11):1079-85. PubMed ID: 3315196
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
    Lai X; Zee BC
    Trials; 2015 Jun; 16():250. PubMed ID: 26037094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting population entering phase III trials: a new stratified adaptive phase II design.
    Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
    Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adaptive designs for single-arm phase II trials in oncology.
    Englert S; Kieser M
    Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.
    Jung SH
    Contemp Clin Trials; 2015 May; 42():9-17. PubMed ID: 25749311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and power.
    Khan I; Sarker SJ; Hackshaw A
    Br J Cancer; 2012 Nov; 107(11):1801-9. PubMed ID: 23169334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of a misspecification of response rates on type I and type II errors, in a phase II Simon design.
    Baey C; Le Deley MC
    Eur J Cancer; 2011 Jul; 47(11):1647-52. PubMed ID: 21493059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies.
    Jones CL; Holmgren E
    Contemp Clin Trials; 2007 Sep; 28(5):654-61. PubMed ID: 17412647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized phase II trials with a prospective control.
    Jung SH
    Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Balanced two-stage designs for phase II clinical trials.
    Ye F; Shyr Y
    Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Two-stage k-sample designs for the ordered alternative problem.
    Shan G; Hutson AD; Wilding GE
    Pharm Stat; 2012; 11(4):287-94. PubMed ID: 22408050
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
    Schlesselman JJ; Reis IM
    Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exact two-stage designs for phase II activity trials with rank-based endpoints.
    Wilding GE; Shan G; Hutson AD
    Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Curtailed two-stage matched pairs design in double-arm Phase II clinical trials.
    Carsten C; Chen P
    J Biopharm Stat; 2016; 26(5):816-22. PubMed ID: 26368314
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An optimal stratified Simon two-stage design.
    Parashar D; Bowden J; Starr C; Wernisch L; Mander A
    Pharm Stat; 2016 Jul; 15(4):333-40. PubMed ID: 26932771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.